By Maureen Meehan A recent clinical trial conducted by Soroka University Medical Center and Israeli medical cannabis company Cannbit-Tikun Olam (TASE:TKUN) showed promising results, especially for treating post-traumatic stress disorder (PTSD), reported the Jerusalem Post. Overall, over two-thirds of patients reported at least moderate improvement with no serious side effects, with 90.8% of treated PTSD patients being classified as therapeutic successes after six months. Nearly half of the patients reported that their quality of life had improved during the time of treatment. Photo by ipopba/Getty Images RELATED: Military Veterans Can Use Medical Marijuana Without Losing Eligibility For Care And Services Other benefits included a decrease in rage attacks, restlessness, nausea and sleep disturbances. Notably, a number of cannabis-medicated patients stopped or reduced their dosages of opioids by 52%, anti-psychotics by 36.9%, anti-epileptics by 35.7% and hypnotics and sedatives by 35.3%.